MX2021009921A - Preformulacion de lipidos de liberacion sostenida y composicion farmacetica de liberacion sostenida inyectable en la forma de una solucion de lipidos que contiene a la misma. - Google Patents

Preformulacion de lipidos de liberacion sostenida y composicion farmacetica de liberacion sostenida inyectable en la forma de una solucion de lipidos que contiene a la misma.

Info

Publication number
MX2021009921A
MX2021009921A MX2021009921A MX2021009921A MX2021009921A MX 2021009921 A MX2021009921 A MX 2021009921A MX 2021009921 A MX2021009921 A MX 2021009921A MX 2021009921 A MX2021009921 A MX 2021009921A MX 2021009921 A MX2021009921 A MX 2021009921A
Authority
MX
Mexico
Prior art keywords
sustained
release
lipid
preformulation
pharmaceutical composition
Prior art date
Application number
MX2021009921A
Other languages
English (en)
Inventor
Young- Joon Park
Sang- Won Jeon
Sook Choi
Original Assignee
Imdpharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imdpharm Inc filed Critical Imdpharm Inc
Publication of MX2021009921A publication Critical patent/MX2021009921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El resultado obtenido mediante la realización de la prueba de liberación in vitro como es descrita anteriormente es mostrado en la FIG. 6. A partir del resultado de la FIG. 6, puede ser confirmado que la composición farmacéutica inyectable de liberación sostenida en la forma de una solución de lípidos obtenida de acuerdo con la presente invención exhibe un patrón de liberación sostenida eficaz durante un largo período de tiempo.
MX2021009921A 2019-02-18 2020-02-17 Preformulacion de lipidos de liberacion sostenida y composicion farmacetica de liberacion sostenida inyectable en la forma de una solucion de lipidos que contiene a la misma. MX2021009921A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190018619A KR102186704B1 (ko) 2019-02-18 2019-02-18 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물
PCT/KR2020/002182 WO2020171491A1 (ko) 2019-02-18 2020-02-17 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물

Publications (1)

Publication Number Publication Date
MX2021009921A true MX2021009921A (es) 2021-10-13

Family

ID=72144366

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009921A MX2021009921A (es) 2019-02-18 2020-02-17 Preformulacion de lipidos de liberacion sostenida y composicion farmacetica de liberacion sostenida inyectable en la forma de una solucion de lipidos que contiene a la misma.

Country Status (9)

Country Link
US (1) US20220125888A1 (es)
EP (1) EP3928762A4 (es)
JP (1) JP7457727B2 (es)
KR (1) KR102186704B1 (es)
CN (1) CN113490487B (es)
AU (1) AU2020225991A1 (es)
CA (1) CA3130252A1 (es)
MX (1) MX2021009921A (es)
WO (1) WO2020171491A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115484935A (zh) * 2020-02-14 2022-12-16 G2G生物公司 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物
WO2023080712A1 (ko) * 2021-11-05 2023-05-11 ㈜아이엠디팜 신규한 서방성 지질 전구 제제 및 이를 포함하는 서방성 주사용 약학 조성물
KR20230115591A (ko) * 2022-01-27 2023-08-03 주식회사 티온랩테라퓨틱스 초기 방출 제어된 지질 융합 데포 조성물 및 이의 제조방법
CN117180281B (zh) * 2023-11-08 2024-02-06 山东则正医药技术有限公司 棕榈酸帕利哌酮制剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
ES2248908T7 (es) * 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
SE9703458D0 (sv) 1997-09-25 1997-09-25 Pharmacia & Upjohn Ab Nicotine compositions and methods of formulation thereof
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
US8865021B2 (en) 2003-11-07 2014-10-21 Camurus Ab Compositions of lipids and cationic peptides
DE602005008247D1 (de) 2004-06-04 2008-08-28 Camurus Ab Flüssige depotformulierungen
KR101494594B1 (ko) * 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586790B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CN106491519B (zh) * 2016-12-09 2020-01-21 广州中大南沙科技创新产业园有限公司 局部麻醉药的立方液晶原位凝胶注射剂及其制备方法
KR102096391B1 (ko) * 2019-10-11 2020-04-06 (주)아이엠디팜 액상결정 구조체를 형성하는 오메가-3-지방산 조성물

Also Published As

Publication number Publication date
KR102186704B1 (ko) 2020-12-04
WO2020171491A1 (ko) 2020-08-27
EP3928762A4 (en) 2022-11-16
EP3928762A1 (en) 2021-12-29
CN113490487B (zh) 2023-04-18
US20220125888A1 (en) 2022-04-28
CA3130252A1 (en) 2020-08-27
AU2020225991A1 (en) 2021-09-02
JP2022520858A (ja) 2022-04-01
JP7457727B2 (ja) 2024-03-28
KR20200100392A (ko) 2020-08-26
CN113490487A (zh) 2021-10-08

Similar Documents

Publication Publication Date Title
MX2021009921A (es) Preformulacion de lipidos de liberacion sostenida y composicion farmacetica de liberacion sostenida inyectable en la forma de una solucion de lipidos que contiene a la misma.
MX351430B (es) Pre-concentrado lipídico de liberación sostenida de una sustancia farmacológicamente activa y una composición farmacéutica que comprende el mismo.
Weller et al. Cytoplasmic lipid bodies of neutrophils: formation induced by cis-unsaturated fatty acids and mediated by protein kinase C.
Philipson et al. Effects of fatty acids on Na+-Ca2+ exchange and Ca2+ permeability of cardiac sarcolemmal vesicles.
PH12015500936A1 (en) Sustained-release lipid pre-concentrate of gnrh analogues and pharmaceutical composition comprising the same
PH12021550328A1 (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
EA200700389A1 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
UA102477C2 (en) Capsule composition
KR910000101A (ko) 효소형성 억제제
EA201490921A1 (ru) Устойчивые составы с контролируемым высвобождением
US20230146709A1 (en) Therapeutic use of compounds
EA200100895A1 (ru) Незаменимые жирные кислоты для предотвращения сердечно-сосудистых приступов
JO3598B1 (ar) الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
TR200102861T2 (tr) Uzun zincirli trigliseridler ve lipofilik surfaktantları içeren oral farmasötik kompozisyonlar.
IL291055B2 (en) Stable formulations of lipids and liposomes
EA201791166A1 (ru) Препараты с контролируемым высвобождением
ES2923149T3 (es) AceFaPC para el tratamiento de enfermedades dependientes de la acetilcolina
PE20011223A1 (es) Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico
NO20082181L (no) Formuleringer av Fispemifen
Myers et al. Studies on ali-esterases and other lipid-hydrolysing enzymes. 1. Inhibition of the esterases and acetoacetate production of liver
PE20080766A1 (es) Sales de benzimidazolil piridil eteres y formulaciones que las contienen
GB1097531A (en) Improvements in or relating to the preparation of cyclopentane derivatives
Brain et al. Actions of phospholipase-A on mast-cell histamine release and paw oedema in the rat [proceedings].
Veryser et al. The influence of the acyl chain on the transdermal penetration-enhancing effect of synthetic phytoceramides
MX2021012356A (es) Formulación para suministro oral de proteínas, péptidos y moléculas pequeñas con poca permeabilidad.